DUBLIN--(BUSINESS WIRE)--The "Danon Disease Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
Danon Disease - Pipeline Insight, 2019 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Danon Disease pipeline landscape is provided which includes the disease overview and Danon Disease treatment guidelines.
The assessment part of the report embraces, in depth Danon Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Danon Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Danon Disease Pipeline Development Activities
The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Danon Disease targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Danon Disease pipeline report covers only one company. Some of the key players include Rocket Pharmaceuticals (RP-L401) etc.
Danon Disease Analytical Perspective
This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition -Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.
Key Topics Covered:
1. Report Introduction
2. Danon Disease (Glycogen Storage Disease Type 2B, Glycogen Storage Disease Type IIb, Lysosomal Glycogen Storage Disease with Normal Acid Maltase)
2.1. Danon Disease Disease Overview
2.2. Danon Disease History
2.3. Danon Disease Symptoms
2.4. Danon Disease Causes
2.5. Danon Disease Pathophysiology
2.6. Danon Disease Diagnosis
3. Danon Disease Current Treatment Patterns
3.1. Treatment Guidelines
4. Danon Disease - Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Danon Disease companies collaborations, Licensing, Acquisition -Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Danon Disease Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing/Partnering) Analysis
4.1.2.2. Danon Disease Acquisition Analysis
4.2. Clinical Assessment of Pipeline Drugs
4.2.1. Assessment by Phase of Development
4.2.2. Assessment by Product Type (Mono/Combination)
4.2.2.1. Assessment by Stage and Product Type
4.2.3. Assessment by Route of Administration
4.2.4. Assessment by Molecule Type
4.2.5. Assessment by MOA
5. Danon Disease Pipeline Therapeutics
5.1. Late Stage Products (Phase-III)
5.1.1. Comparative Analysis
5.2. Mid Stage Products (Phase-II)
5.3. Early Stage Products (Phase-I)
5.4. Pre-clinical and Discovery Stage Products
5.5. Inactive Products
6. Danon Disease -Products Analysis
6.1. Product Profiles
6.1.1. RP-L401- Rocket Pharmaceuticals
6.1.1.1. Product Description
6.1.1.1.1. Product Overview
6.1.1.1.2. Mechanism of Action
6.1.1.2. Research and Development
6.1.1.2.1. Clinical Studies
6.1.1.2.1.1. Detailed Study Description
6.1.1.2.1.2. Study Results
6.1.1.2.1.3. Clinical Trials: Tabular View
6.1.1.3. Product Development Activities
6.1.1.3.1. Tabulated Product Summary
6.1.1.3.1.1. General Description Table
7. Recent Technologies
8. Danon Disease Key Companies
8.1. Rocket Pharmaceuticals
9. Danon Disease Key Products
9.1. RP-L401
10. Dormant and Discontinued Products
10.1. Dormant Products
10.1.1. Reasons for being dormant
10.2. Discontinued Products
10.2.1. Reasons for the discontinuation
11. Danon Disease - Unmet Needs
12. Danon Disease - Future Perspectives
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/ywnu24